Results 81 to 90 of about 282,348 (239)

Real‐World Safety and Effectiveness of JAK Inhibitors in Systemic Sclerosis: A Propensity‐Matched Study From the EUSTAR Cohort

Arthritis Care &Research, EarlyView.
Objective JAK inhibitors (JAKi) have shown promising effects in early‐phase studies of systemic sclerosis (SSc). We aimed to assess the safety and explore the effectiveness of JAKi compared to conventional immunosuppressants in SSc. Methods A longitudinal retrospective study of the European Scleroderma Trials and Research Group (EUSTAR) cohort was ...
Stefano Di Donato, Marie‐Elise Truchetet, Marco Minerba, Oliver Distler, Juan José Alegre Sancho, Yolanda Braun‐Moscovici, Christina Bergmann, Petros Sfikakis, Jeska K. de Vries‐Bouwstra, Murray Baron, Silvia Bellando‐Randone, Lorenzo Dagna, Christopher P. Denton, Madelon C. Vonk, Vanessa Smith, Ivan Castellvi, Gabriela Riemekasten, Andra Balanescu, Masataka Kuwana, Maria De Santis, Kamal Solanki, Anastas Batalov, Vahan Mukuchyan, Marco Matucci‐Cerinic, Yannick Allanore, Francesco Del Galdo, Michael Hughes, EUSTAR Collaborators   +27 more
wiley   +1 more source

Anorectal Dysfunction in Systemic Sclerosis: Clinical Phenotypes and Functional Patterns

Arthritis Care &Research, EarlyView.
Objective The aim of this study was to characterize specific physiologic defects in anorectal dysfunction in systemic sclerosis (SSc) using anorectal manometry (ARM), evaluate associations with gastrointestinal (GI) and extraintestinal clinical phenotypes, and explore potential serologic markers for risk stratification.
Timothy Kaniecki, Alireza Amindarolzarbi, Tsion Abdi, John Clarke, Michael Hughes, Ami A. Shah, Zsuzsanna H. McMahan   +6 more
wiley   +1 more source

Development of a Disease Activity Index for the Assessment of VEXAS Syndrome (VEXAS‐DAI)

Arthritis Care &Research, Accepted Article.
Objective VEXAS syndrome is characterized by a complex spectrum of inflammatory and hematologic manifestations. Clinical research to identify effective therapies is urgently needed but is hindered by the lack of validated outcome measures. A VEXAS‐specific disease activity index (DAI) is an essential tool for reliably capturing changes in disease ...
Kevin Byram, Heřman Mann, Danielle Hammond, Onima Chowdhury, Sinisa Savic, Yohei Kirino, Carmelo Gurnari, Maël Heiblig, Thibault Comont, Arsène Mekinian, Mrinal M. Patnaik, Lachelle D. Weeks, Gary Ho, Adam Al‐Hakim, Scott Goldberg, Marcela A. Ferrada, Sophie Georgin‐Lavialle, Peter C. Grayson, Emma M. Groarke, Bhavisha Patel, Megan Sullivan, Sarah A. Buckley, Bryan G. Harder, Raman Garcha, David B. Beck, Matthew J. Koster   +25 more
wiley   +1 more source

Obituary: Dr. Eugene Garfield (1925-2017)

The Pan African Medical Journal, 2017
It is with great sadness that we announce the death of Dr. Eugene Garfield. Dr. Garfield died on Sunday 26 February 2017. He was 91. Dr. Garfield is credited as the inventor of the journal impact factor.
Allan Mwesiga
doaj   +1 more source

Clinician and patient factors associated with long‐term glucocorticoid use in people with rheumatoid arthritis on advanced therapies

Arthritis Care &Research, Accepted Article.
Background Despite guideline recommendations, long‐term glucocorticoid (GC) use is common in rheumatoid arthritis (RA). We conducted a clinician survey nested within a large registry to identify patient and clinician factors associated with GC use. Methods Clinicians contributing patients to the CorEvitas Rheumatoid Arthritis registry were surveyed ...
Michael D. George, George Reed, Matthew D. Kearney, Peter F. Cronholm, Kevin Kane, Jeffrey R. Curtis, Dimitrios A. Pappas, Joel M. Kremer   +7 more
wiley   +1 more source

Short‐term response to biologic therapy in psoriatic arthritis (PsA) is not influenced by disease duration at initiation of therapy

Arthritis Care &Research, Accepted Article.
Objectives We aimed to determine whether the short‐term response to biologics in biologic‐naïve psoriatic arthritis (PsA) is better in patients initiating biologic treatment early in the disease course. Methods PsA patients who started biologic therapy from the year 2000 to 2025 were included for analysis. Patients considered in the early treatment (ET)
Sung Min Cho, Shangyi Gao, Daniel Pereira, Richard J. Cook, Dafna D. Gladman   +4 more
wiley   +1 more source

Caregiver Perspectives on the Burden of Disease and Treatment in Uncontrolled Gout

Arthritis Care &Research, EarlyView.
Objective Uncontrolled gout (UG) refers to persistently elevated serum urate (SU) levels >6 mg/dL and ongoing gout symptoms despite use of urate‐lowering therapy (ULT). The objective of this study was to evaluate the burden associated with informal caregiving for individuals with UG.
Angelo Gaffo, Bhavisha Desai, Abiola Oladapo, Nana Kragh, Rebekah Zincavage, Brad Padilla, Naomi Schlesinger   +6 more
wiley   +1 more source

Employment Trajectories of Patients with Systemic lupus erythematosus (SLE) and Factors Driving Transitions Between States

Arthritis Care &Research, Accepted Article.
Objective Systemic lupus erythematosus (SLE) significantly impacts employment capacity. This study aimed to investigate the impact of burden of disease activity, damage, and treatment on employment outcomes and transitions in patients with SLE. Materials and Methods Using data from a single center, we analyzed employment transitions, adjusted mean ...
Javier Mencia‐Ledo, Zahi Touma, Laura Whittall Garcia, Dafna Gladman, Behdin Nowrouzi‐Kia   +4 more
wiley   +1 more source

Altmetrics Challenges in Research Evaluation: A Thematic Analysis

مدیریت اطلاعات سلامت, 2017
Introduction: Despite the advantages of altmetrics in research evaluation, it encounters many challenges as a nascent field impacted by web dynamism. The present study attempted to identify the challenges of employing altmetrics’ in evaluating research ...
Hajar Sotudeh, Masumeh Ravaie, Mahdieh MirzaBeigi, Zahra Mazarei   +3 more
doaj  

NFDI MatWerk Ontology (MWO): A BFO‐Compliant Ontology for Research Data Management in Materials Science and Engineering

Advanced Engineering Materials, EarlyView.
This article presents the NFDI‐MatWerk Ontology (MWO), a Basic Formal Ontology‐based framework for interoperable research data management in materials science and engineering (MSE). Covering consortium structures, research data management resources, services, and instruments, MWO enables semantic integration, Findable, Accessible, Interoperable, and ...
Hossein Beygi Nasrabadi, Ebrahim Norouzi, Kostiantyn Hubaiev, Jörg Waitelonis, Harald Sack   +4 more
wiley   +1 more source